XXXX and @entity1487 combination chemotherapy in advanced and/or metastatic @entity14 : a phase II study.

@entity1 @entity137 @entity390 @entity295 @entity548 @entity75 @entity5 @entity900 @entity391 @entity14 @entity236 @entity204 @entity1487
The possible synergism of @entity900 (P) and @entity1487 was studied in 38 consecutive @entity1 with advanced or metastatic @entity14 . @entity900 60 mg/m2 i.v.q. 4 weeks and @entity1487 600 mg/m2 i.v. weekly were administered for at least 2 cycles, on an out- @entity1 basis, to 24 males and 14 females with a median age of 57 years and a median PS of 80 (Karnofsky). @entity75 were: primary unresectable @entity5 in 2 @entity1 , local recurrence in 11, liver, lung, bone and soft tissue metastases in 21, 7, 2 and 3 @entity1 respectively. With a median number of 3 cycles administered to 35 evaluable @entity1 , 6 partial responses, 16 unchanged and 13 progressions were observed. Responses were observed in the liver (2 @entity1 ), lungs (1) and soft tissues (3). Median remission duration was 15 weeks, median duration of 'unchanged' was 12 weeks. The overall median survival was 24 weeks (30.5 weeks for responders and 22.5 weeks for non-responders). Six @entity1 were pretreated with chemotherapy not containing @entity900 (mainly adjuvant @entity1487 ). None of them responded. @entity137 was very tolerable with moderate @entity390 , @entity391 and alopecia in the majority of the @entity1 ; @entity236 was generally mild with no blood transfusions required, no complications of myelosuppression ( @entity295 or @entity548 ) and no chemotherapy-related @entity204 . In this experience the combination of low dose @entity900 with @entity1487 , does not appear to significantly enhance @entity1487 @entity137 and the response rate is not superior to that reported with @entity1487 alone. However, better designed schedule combinations with optimal doses, sequences and exposure time of the 2-drug regimen, seem necessary to obtain the biochemical events that support the potentiation.
